Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS.

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain and to decrease inflammation. Several clinical studies have reported that NSAIDs inhibit uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes. Therefore, the study evaluated the inhibitory potential of 15 NSAIDs on the activities of six UGT isoforms (i.e. UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) in human liver microsomes (HLMs). Among the 15 NSAIDs tested here, mefenamic acid and diclofenac inhibited all UGTs tested in this study. Piroxicam and niflumic acid inhibited UGT1A9 activity (IC50 = 73.8 μm and 0.38 μm, respectively) and naproxen selectively inhibited UGT2B7 activity (IC50 = 53.1 μm), whereas it did not inhibit the other UGTs tested (IC50 > 200 μm). Diflunisal inhibited the UGT1A1 (IC50 = 33.0 μm) and UGT1A9 (IC50 = 19.4 μm). Acetaminophen, fenoprofen, ibuprofen, ketoprofen, meloxicam, phenylbutazone, salicylic acid and sulindac showed negligible inhibitory effects on the six UGTs (IC50 > 100 μm). These results suggest that some NSAIDs have the potential to inhibit UGTs in vitro.

[1]  Kwang-Hyeon Liu,et al.  Screening of six UGT enzyme activities in human liver microsomes using liquid chromatography/triple quadrupole mass spectrometry. , 2014, Rapid communications in mass spectrometry : RCM.

[2]  Dong-Hyun Kim,et al.  In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry , 2014, Drug Metabolism and Disposition.

[3]  Hea‐Young Cho,et al.  Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. , 2013, Biomedical chromatography : BMC.

[4]  P. Shrivastav,et al.  Sensitive and selective determination of diflunisal in human plasma by LC-MS. , 2013, Journal of chromatographic science.

[5]  S. Griffen,et al.  Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin , 2013, Diabetes, obesity & metabolism.

[6]  S. Dhaneshwar,et al.  A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. , 2012, Biomedical chromatography : BMC.

[7]  P. Marquet,et al.  Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry. , 2012, Analytical biochemistry.

[8]  K. Knights,et al.  Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation , 2011, Drug Metabolism and Disposition.

[9]  K. Knights,et al.  Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. , 2009, British journal of clinical pharmacology.

[10]  M. Court,et al.  Effect of the β‐glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP‐glucuronosyltransferases , 2008, The Journal of pharmacy and pharmacology.

[11]  H. Kamimura,et al.  Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. , 2008, Journal of pharmaceutical sciences.

[12]  G. S. Walker,et al.  Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. , 2007, Chemical research in toxicology.

[13]  H. Kamimura,et al.  Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver , 2007, European Journal of Clinical Pharmacology.

[14]  H. Kamimura,et al.  Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes , 2007, European Journal of Clinical Pharmacology.

[15]  H. Kamimura,et al.  In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans , 2006, Biopharmaceutics & drug disposition.

[16]  J. Miners,et al.  SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES , 2006, Drug Metabolism and Disposition.

[17]  Takashi Usui,et al.  In vitro inhibitory effects of non‐steroidal anti‐inflammatory drugs on 4‐methylumbelliferone glucuronidation in recombinant human UDP‐glucuronosyltransferase 1A9—potent inhibition by niflumic acid , 2006, Biopharmaceutics & drug disposition.

[18]  J. Potter,et al.  GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[19]  R. Laufer,et al.  DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY , 2005, Drug Metabolism and Disposition.

[20]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[21]  H. Kamimura,et al.  In Vitro inhibitory effects of non‐steroidal antiinflammatory drugs on UDP‐glucuronosyltransferase 1A1‐catalysed estradiol 3β‐glucuronidation in human liver microsomes , 2005, Biopharmaceutics & drug disposition.

[22]  A. Prémaud,et al.  IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM , 2005, Drug Metabolism and Disposition.

[23]  Y. Uesawa,et al.  Substrate specificity of human hepatic udp-glucuronosyltransferases. , 2005, Methods in enzymology.

[24]  Chong-K. Kim,et al.  Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography. , 2005, Biomedical chromatography : BMC.

[25]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[26]  Qin Hao,et al.  Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[27]  A. Galetin,et al.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. Verbesselt,et al.  Pharmacokinetic interaction between indomethacin and diflunisal , 2004, European Journal of Clinical Pharmacology.

[29]  M. Braun,et al.  Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  A. Li,et al.  Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[31]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.